Boothbay Fund Management’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Boothbay Fund Management’s Portfolio ATXI Stock Details ATXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-41,089	Closed	-$82.2K	–	1882
2024 Q4	$82.2K	Buy	+41,089	New	+$83.4K	﹤0.01%	1311

Boothbay Fund Management's ATXI Position: Q1 2025 in Review

Boothbay Fund Management sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q1 2025, closing a stake of 41,089 shares — an estimated $82.2K sold.

Boothbay Fund Management first reported a position in ATXI in Q4 2024 and held it in 1 quarter. The position peaked at $82.2K in Q4 2024. 0 funds tracked by Wall St. Rank hold ATXI as of Q1 2025.

Boothbay Fund Management reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Boothbay Fund Management sold 41,089 Avenue Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $82.2K.
Boothbay Fund Management first reported a position in Avenue Therapeutics, Inc. Common Stock in Q4 2024 and held it in 1 quarter.
Boothbay Fund Management's Avenue Therapeutics, Inc. Common Stock position peaked at $82.2K in Q4 2024.
0 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.